SCHEMBL6565191

SCHEMBL6565191

CCCS(=O)(=O)NCCc1cccc(C(C)CNS(=O)(=O)CCC)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 3/20 0.50
TBXAS1 P24557 1/20 0.43
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
AKR1C3 P42330 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6561702 0.88 GRIA4 (0.52) GRIA4
SCHEMBL6563308 0.85 GRIA4 (0.56) GRIA4TBXAS1ALDH1A1KDM4EHTT
SCHEMBL6554408 0.80 GRIA4 (0.67) GRIA4SMN1; SMN2
SCHEMBL338392 0.80 GRIA4 (0.67) GRIA4SMN1; SMN2
SCHEMBL6759326 0.80 GRIA4 (0.67) GRIA4SMN1; SMN2
SCHEMBL6565186 0.80 GRIA4 (0.59) GRIA4ALDH1A1L3MBTL1NPSR1
SCHEMBL6562902 0.80 GRIA4 (0.53) GRIA4ALDH1A1SMN1; SMN2L3MBTL1NPC1
SCHEMBL6563307 0.79 GRIA4 (0.65) GRIA4ALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6565123 0.78 GRIA4 (0.68) GRIA4
SCHEMBL6563278 0.77 GRIA4 (0.54) GRIA4ALDH1A1HTTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1296945-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
WO-2001096289-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 GRIA4 17/4885TBXAS1 2334/4885ALDH1A1 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.